Browse result page of CancerPDF Database

Please click on CancerPDF_ID for detailed information about peptide.

CancerPDF_IDPeptide seqProtein NameFluidMass/ZProfiling TechniqueCancer Type Expression RegulationPUBMED ID
CancerPDF_ID1019 LAEGGGVRFibrinopeptide ASerum758.45MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.66, 0.95 and 0.65 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1020 FLAEGGGVRFibrinopeptide ASerum905.5MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 0.97, 0.73 and 1.48 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1021 DFLAEGGGVRFibrinopeptide ASerum1020.47MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.28, 0.28 and 0.47 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1022 GDFLAEGGGVRFibrinopeptide ASerum1077.53MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.54, 0.5 and 0.97 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1023 EGDFLAEGGGVRFibrinopeptide ASerum1206.57MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.5, 0.44 and 0.69 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1024 GEGDFLAEGGGVRFibrinopeptide ASerum1263.6MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.2, 0.24 and 0.23 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1025 SGEGDFLAEGGGVRFibrinopeptide ASerum1350.64MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.47, 0.46 and 0.35 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1026 DSGEGDFLAEGGGVRFibrinopeptide ASerum1465.65MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.66, 0.55 and 0.8 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1027 ADSGEGDFLAEGGGVRFibrinopeptide ASerum1536.68MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.58, 0 and 0.54 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1028 GSESGIFTNTKESSSHHPGIAEFPSRGFibrinogen alpha chainSerum2816.25MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 68, 223 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1029 SSSYSKQFTSSTSYNRGDSTFESFibrinogen alpha chainSerum2553.01MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.35, 1.31 and 1.5 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1030 SSSYSKQFTSSTSYNRGDSTFESKSFibrinogen alpha chainSerum2768.3MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.77, 0.03 and 0.98 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1031 SSSYSKQFTSSTSYNRGDSTFESKSYFibrinogen alpha chainSerum2931.29MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in bladder cancer and upregulated in prostate cancer vs normal with Ratio of median intensity (patients/Controls) = 1.24, 0.13 and 0.97 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1032 SSSYSKQFTSSTSYNRGDSTFESKSYKMFibrinogen alpha chainSerum3190.4MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.52, 0 and 0.94 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1033 SSSYSKQFTSSTSYNRGDSTFESKSYKMAFibrinogen alpha chainSerum3261.4MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.33, 0.08 and 0.74 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1034 SSYSKQFTSSTSYNRGDSTFEFibrinogen alpha chainSerum2379.03MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.57, 0.22 and 1.71 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1035 NAFibrinogen alpha chainSerum3206.34MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1036 NAFibrinogen alpha chainSerum3277.39MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1037 DEAGSEADHEGTHSTKRGHAKSRPVFibrinogen alpha chainSerum2659.03MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.37, 1.18 and 2.45 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1038 SYKMADEAGSEADHEGTHSTKRGHAKSRPVFibrinogen alpha chainSerum3239.22MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1039 HWESASLLComplement C3fSerum942.44MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For Breast (Lower) and for Bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.74, 5.18 and 0.58 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1040 IHWESASLLComplement C3fSerum1055.6MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 227, 1051 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1041 RIHWESASLLComplement C3fSerum1211.7MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =7.86, 10.8 and 0.01 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1042 HRIHWESASLLComplement C3fSerum1348.7MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1043 THRIHWESASLLComplement C3fSerum1449.76MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1885, 2646 and 437 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1044 ITHRIHWESASLLComplement C3fSerum1562.84MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.79, 1.13 and 0.54 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1045 KITHRIHWESASLLComplement C3fSerum1690.9MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =4.05, 6.85 and 1.01 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1046 SKITHRIHWESASLLComplement C3fSerum1777.94MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =4.37, 7.7 and 0.96 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1047 SSKITHRIHWESASLLComplement C3fSerum1864.95MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For Prostate & bladder (Higher) and for breast (Lower) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =2.18, 3.33 and 0.3 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1048 SSKITHRIHWESASLLRComplement C3fSerum2021.06MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1049 SSKITHRIHWESASLComplement C3fSerum1751.88MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.82, 5.7 and 1.36 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1050 NGFKSHALQLNNRComplement C4 precursorSerum1498.91MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 809 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1051 NGFKSHALQLNNRQComplement C4 precursorSerum1626.85MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1052 NGFKSHALQLNNRQIComplement C4 precursorSerum1739.93MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.75, 0.66 and 2.75 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1053 NGFKSHALQLNNRQIRComplement C4 precursorSerum1895.99MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.27, 3.33 and 2.95 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1054 GLEEELQFSLGSKINVComplement C4 precursorSerum1762.87MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.62, 0.01 and 3.16 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1055 GLEEELQFSLGSKINVKVGGNSComplement C4 precursorSerum2305.2MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1056 GLEEELQFSLGSKINVKVGGNSKGTLComplement C4 precursorSerum2704.13MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =61, 49 and 133 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1057 GLEEELQFSLGSKINVKVGGNSKGTLKVLRComplement C4 precursorSerum3200.52MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1058 TLEIPGNSDPNMIPDGDFNSYVRComplement C4 precursorSerum2551.06MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1059 HAAYHPFInter-alpha-trypsin inhibitor heavy chain H4Serum842.4MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in Prostate cancer vs normal,Downregulated in Bladder cancer vs normal with Ratio of median intensity (patients/Controls) =1.49, 0.01 and 1.04 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1060 GLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H5Serum1786.86MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.39, 2.88 and 2.3 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1061 QLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H6Serum2028.01MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1062 SRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H7Serum2271.14MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =4.58, 2.64 and 1.46 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1063 SSRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H8Serum2358.09MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =100, 73 and 531 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1064 GVLSSRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H9Serum2627.48MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.24, 0.26 and 1.07 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1065 PGVLSSRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H10Serum2724.48MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.75, 6.17 and 1.64 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1066 MNFRPGVLSSRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H11Serum3272.5MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 1277 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1067 QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPFInter-alpha-trypsin inhibitor heavy chain H12Serum3970.97MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 957 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1068 QLGLPGPPDVPDHAAYHPFRInter-alpha-trypsin inhibitor heavy chain H13Serum2183.91MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.71, 1.79 and 2.83 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1069 HAAYHPFRInter-alpha-trypsin inhibitor heavy chain H14Serum998.45MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =121, 256 and 147 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1070 NVHSGSTFFKYYLQGAKIPKPEASFSPRInter-alpha-trypsin inhibitor heavy chain H15Serum3156.52MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.43, 10.68 and 1.33 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1071 NVHSAGAAGSRMNFRPGVLSSPRO1851(ITIH4 splice variant)Serum2115.01MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.22, 12.23 and 10.61 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1072 ATEHLSTLSEKAKPALEDLApolipoprotein A-ISerum2052.89MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =105, 306 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1073 QGLLPVLESFKVSFLSALEEYTKKLNTQApolipoprotein A-ISerum3182.46MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.74, 6.36 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1074 VSFLSALEEYTKKLNTQApolipoprotein A-ISerum1971.16MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 641 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1075 ELQEGARQKLHELQEApolipoprotein A-ISerum1807.78MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1076 AELQEGARQKLHELQEKLSPLGEEMRDRAApolipoprotein A-ISerum3377.45MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1077 ISASAEELRQRLAPLAEDVRGNLApolipoprotein A-IVSerum2508.16MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.38, 1.2 and 7.96 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1078 SLAELGGHLDQQVEEFApolipoprotein A-IVSerum1771.81MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =148, 220 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1079 GNTEGLQKSLAELGGHLDQQVEEFApolipoprotein A-IVSerum2599.18MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1080 GNTEGLQKSLAELGGHLDQQVEEFRApolipoprotein A-IVSerum2755.2MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.11, 12.37 and 1.22 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1081 SLAELGGHLDQQVEEFRApolipoprotein A-IVSerum1927.94MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =79, 671 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1082 DVSSALDKLKEFGNTLEDKARELISApolipoprotein C-ISerum2778.15MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1083 TVGSLAGQPLQERAQAWGERLApolipoprotein ESerum2267.07MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1084 AATVGSLAGQPLQERAQAWGERLApolipoprotein ESerum2409.13MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =97, 2124 and 109 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1085 AATVGSLAGQPLQERAQAWGERLRApolipoprotein ESerum2565.45MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 902 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1086 HFFFPKClusterin precursorSerum822.41MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.15, 4.66 and 0.76 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1087 HFFFPKSRIVClusterin precursorSerum1277.71MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =251, 1406 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1088 RPPGFSPFBradykinin (and des-Arg bradykinin)Serum904.48MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.06, 0.79 and 1.62 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1089 RPPGFSPFRBradykinin (and des-Arg bradykinin)Serum1060.57MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =0.77, 0.43 and 1.9 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1090 NABradykinin (and des-Arg bradykinin)Serum920.41MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1091 NABradykinin (and des-Arg bradykinin)Serum1076.53MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1092 NLGHGHKHERDQGHGHQHMW KininogenSerum1943.88MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.58, 141 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1093 KHNLGHGHKHERDQGHGHQHMW KininogenSerum2209.08MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.72, 2.07 and 1.56 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1094 GHGLGHGHEQQHGLGHGHKFHMW KininogenSerum2126.94MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1095 AVPPNNSNAAEDDLPTVELQGVVPRFactor XIIIaSerum2602.15MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.84, 2.3 and 4.73 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1096 ALGISPFHEHAEVVFTANDSGPRTranstherin precursor (‘prealbumin’)Serum2451.11MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.02, 1.17 and 3.07 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1097 PDAPRIKKIVQKKLAGDESADPlatelet basic protein PrecursorSerum2279.18MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID3416 YTKVVHYRKWIKDTIVANPPuromycin-sensitive aminopeptidaseUrine2332.3MALDI digital ion trap (DIT) TOFProstate cancer Differentially expressed between normal and patients 25233230